ROMVIMZA (Vimseltinib) Patent Expiration, LOE Window & CMS Spending

ROMVIMZA (Vimseltinib) by Deciphera: FDA Orange Book core substance LOE 2045-04-30, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $26,128 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorDeciphera
FDA Application & PathwayN219304 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2045-04-30
Last Listed Patent or Exclusivity Date2045-04-30
Orange Book Patents (*PED Extensions)39 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($26,128 intro WAC)